Transcriptional pharmacology of neurodegenerative disorders: Novel venue towards neuroprotection against excitotoxicity?

Molecular Psychiatry

Volumn 2, Issue 3, 1997, Pages 192-194

  Grilli, M ^a   Memo, M ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SALICYLIC ACID DERIVATIVE; TRANSCRIPTION FACTOR;

HUMAN; NERVE DEGENERATION; NEUROPROTECTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030917024     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000252     Document Type: Short Survey

References (15)

1. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623-634.
2. Lipton BT, Rosenberg PA. Excitatory aminoacids as a final common pathway for neurological disorders. New Engl J Med 1995; 330: 613-622.
3. Memo M, Pizzi M, Valerio A, Grilli M, Spano PF. Molecular mechanisms of glutamate-induced neurodegeneration. Int Rev Psych 1995; 7: 339-348.
4. Grilli M, Chiu J-S, Lenardo MJ. NF-κB and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993; 143: 1-62.
5. Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by aspirin and sodium salicylates through blockade of NF-κB activation. Science 1996; 274: 1383-1385.
6. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Bauerle PA. Constitutive NF-κB activity in neurons. Mol Cell Biol 1994; 14: 3981-3992.
7. Kaltschmidt C, Kaltschmidt B, Baeuerle PA. Stimulation of ionotropic glutamate receptors activates transcription factor NF-κB in primary neurons. Proc Natl Acad Sci USA 1995; 92: 9618-9622.
8. Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-κB by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA 1995; 92: 9077-9081.
9. Grilli M, Ribola M, Alberici A, Valerio A, Memo M, Spano PF. Identification and characterization of a NF-κB/Rel binding site in the regulatory region of the Amyloid Precursor Protein gene. J Biol Chem 1995; 270: 26774-26777.
10. Grilli M, Goffi F, Memo M, Spano PF. Interleukin-1β and glutamate activate the NF-κB/Rel binding site from the regulatory region of the Amyloid Precursor Protein gene in primary neuronal cultures. J Biol Chem 1996; 271: 15002-15007.
11. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218.
12. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Manuskhani L, Willson P, Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
13. Kopp E, Ghosh S. Inhibition of NF-κB activity by sodium salicylate and aspirin. Science 1994; 265: 956-959.
14. Van SD, Van SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier JL, Stern D. Non-enzymatically glycated tau in Alzheimer's disease induces oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nature Medicine 1995; 1: 693-699.
15. Terai K, Matsuo A, McGeer P. Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 1996; 735: 159-169.